The Drugs Controller General of India has given its approval to Bharat Biotech for trials of its intranasal Covid booster dose in India. The trial will be done on 900 subjects.
The Drugs Controller General of India (DCGI) has given its approval to Bharat Biotech for trials of its intranasal Covid booster dose in India.
Best Online Casinos for Real Money in India 2022 : Leo188.com
The trial will be done on 900 subjects.
DCGI’s Subject Expert Committee (SEC) gave an ‘in-principle’ approval to Bharat Biotech for the ‘phase-III booster dose study’ for its intranasal Covid vaccine and asked it to submit protocols for approval 3 weeks ago.
